Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Intangibles (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Intangibles data on record, last reported at $31.7 million in Q4 2025.

  • For Q4 2025, Intangibles changed N/A year-over-year to $31.7 million; the TTM value through Dec 2025 reached $31.7 million, changed N/A, while the annual FY2025 figure was $31.7 million, N/A changed from the prior year.
  • Intangibles reached $31.7 million in Q4 2025 per LCTX's latest filing, roughly flat from $31.7 million in the prior quarter.
  • Across five years, Intangibles topped out at $66.1 million in Q4 2022 and bottomed at $22000.0 in Q4 2023.
  • Average Intangibles over 5 years is $36.8 million, with a median of $46.5 million recorded in 2024.
  • Peak YoY movement for Intangibles: tumbled 99.97% in 2023, then dropped 0.26% in 2024.
  • A 5-year view of Intangibles shows it stood at $46.9 million in 2021, then soared by 41.07% to $66.1 million in 2022, then crashed by 99.97% to $22000.0 in 2023, then skyrocketed by 211445.45% to $46.5 million in 2024, then plummeted by 31.89% to $31.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $31.7 million in Q4 2025, $31.7 million in Q2 2025, and $46.5 million in Q2 2024.